Real‐world use of the updated refractory epilepsy screening tool for Lennox–Gastaut syndrome
Epilepsia Open · 2024
DOI: 10.1002/epi4.12952 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia Open, 2024. Verfasst von Steven M Wolf und 7 weiteren Autor:innen. Beteiligte Einrichtung: Boston Children's Hospital Physicians, Hawthorne, New York, USA. Hauptthemen laut MEDLINE: Lennox Gastaut Syndrome, Drug Resistant Epilepsy, Electroencephalography. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jazz Pharmaceuticals, Inc., Jazz Pharmaceuticals.
Abstract (Originalsprache)
Objective
To evaluate the Refractory Epilepsy Screening Tool for Lennox–Gastaut Syndrome (REST‐LGS) for real‐world identification of LGS in adults and to develop a scoring system for the tool.
Methods
A retrospective chart review of adults with drug resistant epilepsy (DRE) and intellectual development disorder (IDD) was conducted by 2 primary care providers blinded to diagnosis. The REST‐LGS was designed via the Modified Delphi Consensus and was previously validated. This tool consists of 8 criteria (4 major, 4 minor) considered indicative of LGS. To account for missing data in the earlier validation study and to evaluate applicability in a real‐world setting, the REST‐LGS was refined to include a scoring system in which major criteria were more heavily weighted than minor criteria, producing categories of “likely” (>11 points), “possible” (8–11 points), and “unlikely” (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Boston Children's Hospital Physicians, Hawthorne, New York, USA.
- New York Medical College, Valhalla, New York, USA.
- Tufts University School of Medicine, Boston, Massachusetts, USA.
- Johns Hopkins School of Medicine, Biomedical Informatics and Data Science, Baltimore, Maryland, USA.
- The Children's Hospital at TriStar Centennial, Nashville, Tennessee, USA.
- Jazz Pharmaceuticals, Inc., Carlsbad, California, USA.
ORCID-Profile: Steven M Wolf, Patricia E McGoldrick
Förderung
- Jazz Pharmaceuticals, Inc.
- Jazz Pharmaceuticals
Zitieren
APA
Wolf, S. M., Boyce, D., Peña, P., Piña-Garza, J. E., Roland, J. J., Thomas, B., Zogejani, D., & McGoldrick, P. E. (2024). Real‐world use of the updated refractory epilepsy screening tool for Lennox–Gastaut syndrome. Epilepsia Open. https://doi.org/10.1002/epi4.12952
Vancouver
Wolf SM, Boyce D, Peña P, Piña-Garza JE, Roland JJ, Thomas B, et al. Real‐world use of the updated refractory epilepsy screening tool for Lennox–Gastaut syndrome. Epilepsia Open. 2024. doi:10.1002/epi4.12952
BibTeX
@article{Wolf2024,
author = {Wolf, Steven M and Boyce, Danielle and Peña, Patricia and Piña-Garza, Jesus Eric and Roland, Jessica J and Thomas, Bethany and Zogejani, Donika and McGoldrick, Patricia E},
title = {Real‐world use of the updated refractory epilepsy screening tool for Lennox–Gastaut syndrome},
journal = {Epilepsia Open},
year = {2024},
doi = {10.1002/epi4.12952}
}
EUVIMED